Hexagon Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,651
| Closed | -$1.6M | – | 80 |
|
|
2025
Q1 | $1.6M | Sell |
7,651
-324
| -4% | -$67.9K | 0.3% | 30 |
|
|
2024
Q4 | $1.42M | Buy |
7,975
+553
| +7% | +$98.3K | 0.26% | 33 |
|
|
2024
Q3 | $1.47M | Sell |
7,422
-409
| -5% | -$80.8K | 0.29% | 26 |
|
|
2024
Q2 | $1.34M | Sell |
7,831
-549
| -7% | -$94.2K | 0.29% | 27 |
|
|
2024
Q1 | $1.53M | Buy |
8,380
+636
| +8% | +$116K | 0.34% | 20 |
|
|
2023
Q4 | $1.2M | Sell |
7,744
-386
| -5% | -$59.8K | 0.29% | 26 |
|
|
2023
Q3 | $1.21M | Buy |
8,130
+981
| +14% | +$146K | 0.32% | 26 |
|
|
2023
Q2 | $963K | Sell |
7,149
-682
| -9% | -$91.9K | 0.25% | 36 |
|
|
2023
Q1 | $1.25M | Buy |
7,831
+747
| +11% | +$119K | 0.35% | 30 |
|
|
2022
Q4 | $1.14M | Sell |
7,084
-755
| -10% | -$122K | 0.33% | 31 |
|
|
2022
Q3 | $1.05M | Buy |
7,839
+3,911
| +100% | +$525K | 0.31% | 33 |
|
|
2022
Q2 | $602K | Buy |
3,928
+531
| +16% | +$81.4K | 0.18% | 67 |
|
|
2022
Q1 | $551K | Sell |
3,397
-238
| -7% | -$38.6K | 0.15% | 87 |
|
|
2021
Q4 | $492K | Sell |
3,635
-20
| -0.5% | -$2.71K | 0.13% | 91 |
|
|
2021
Q3 | $394K | Buy |
3,655
+513
| +16% | +$55.3K | 0.11% | 96 |
|
|
2021
Q2 | $354K | Buy |
3,142
+9
| +0.3% | +$1.01K | 0.1% | 105 |
|
|
2021
Q1 | $339K | Buy |
3,133
+95
| +3% | +$10.3K | 0.09% | 100 |
|
|
2020
Q4 | $325K | Buy |
3,038
+201
| +7% | +$21.5K | 0.1% | 90 |
|
|
2020
Q3 | $250K | Buy |
+2,837
| New | +$250K | 0.08% | 98 |
|